drugset / Trial / NCT00174434

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

NCT00174434

Phase 1 Completed 22 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

Timeline

Start
2005-09
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 25 mg Oral
Subject Sunitinib Small molecule 37.5 mg Oral
Background Paclitaxel Small molecule 90 mg/m2 Intravenous

Indications